clinical trial · NCT01229254
Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter
Portola Pharmaceuticals·phase2·completed·n = 189
Atrial FibrillationAtrial FlutterAmiodaroneBetrixaban 60 mgBetrixaban 90 mgBetrixaban 30 mg
brief summary
The primary purpose of this study is to optimize drug exposure in the target population.
started
Sep 1, 2010
primary completion
Dec 1, 2010
completion
Apr 1, 2011
last updated
Aug 7, 2023
official title
A Phase II, Open-label, Dose Exposure Confirmation Study to Evaluate the Pharmacokinetics and Safety and Tolerability of Betrixaban (MK-4448) in Adult Patients With Nonvalvular Atrial Fibrillation or Atrial Flutter
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol